Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III, Randomized, Open-Label, Parallel-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of 177Lu-NYM032 Injection in Participants With Progressive, PSMA-Positive Metastatic Castration-Resistant Prostate Cancer (mCRPC)

NCT07795268 is registered in ClinicalTrials.gov with Norroy Bioscience Co., LTD as lead sponsor.

NCT NCT07795268
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07795268 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III, Randomized, Open-Label, Parallel-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of 177Lu-NYM032 Injection in Participants With Progressive, PSMA-Positive Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Lead sponsor
Norroy Bioscience Co., LTD
Phase
Phase 3
Overall status
Not yet recruiting
Start date
August 31, 2026
Completion date
August 31, 2029
Enrollment
600 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

prostate cancer